Nanoparticle encapsulation and controlled release of a hydrophobic kinase inhibitor

Three stage mathematical modeling and parametric analysis

Armando Lucero-Acuña, Roberto Z Guzman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A mathematical model of drug release that incorporates the simultaneous contributions of initial burst, nanoparticle degradation-relaxation and diffusion was developed and used to effectively describe the release of a kinase inhibitor and anticancer drug, PHT-427. The encapsulation of this drug into PLGA nanoparticles was performed by following the single emulsion-solvent evaporation technique and the release was determined in phosphate buffer pH 7.4 at 37 °C. The size of nanoparticles was obtained in a range of 162-254 nm. The experimental release profiles showed three well defined phases: an initial fast drug release, followed by a nanoparticle degradation-relaxation slower release and then a diffusion release phase. The effects of the controlled release most relevant parameters such as drug diffusivity, initial burst constant, nanoparticle degradation-relaxation constant, and the time to achieve a maximum rate of drug release were evaluated by a parametrical analysis. The theoretical release studies were corroborated experimentally by evaluating the cytotoxicity effectiveness of the inhibitor AKT/PDK1 loaded nanoparticles over BxPC-3 pancreatic cancer cells in vitro. These studies show that the encapsulated inhibitor AKT/PDK1 in the nanoparticles is more accessible and thus more effective when compared with the drug alone, indicating their potential use in chemotherapeutic applications.

Original languageEnglish (US)
Article number15053
Pages (from-to)249-257
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume494
Issue number1
DOIs
StatePublished - Oct 15 2015

Fingerprint

Nanoparticles
Phosphotransferases
Pharmaceutical Preparations
Theoretical Models
Emulsions
Pancreatic Neoplasms
Buffers
Phosphates
Drug Liberation

Keywords

  • Controlled release
  • Mathematical modeling
  • Nanoparticles
  • Pancreatic cancer
  • Parametric analysis
  • PLGA

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{b15d80354260484fafcc99a83c49bad4,
title = "Nanoparticle encapsulation and controlled release of a hydrophobic kinase inhibitor: Three stage mathematical modeling and parametric analysis",
abstract = "A mathematical model of drug release that incorporates the simultaneous contributions of initial burst, nanoparticle degradation-relaxation and diffusion was developed and used to effectively describe the release of a kinase inhibitor and anticancer drug, PHT-427. The encapsulation of this drug into PLGA nanoparticles was performed by following the single emulsion-solvent evaporation technique and the release was determined in phosphate buffer pH 7.4 at 37 °C. The size of nanoparticles was obtained in a range of 162-254 nm. The experimental release profiles showed three well defined phases: an initial fast drug release, followed by a nanoparticle degradation-relaxation slower release and then a diffusion release phase. The effects of the controlled release most relevant parameters such as drug diffusivity, initial burst constant, nanoparticle degradation-relaxation constant, and the time to achieve a maximum rate of drug release were evaluated by a parametrical analysis. The theoretical release studies were corroborated experimentally by evaluating the cytotoxicity effectiveness of the inhibitor AKT/PDK1 loaded nanoparticles over BxPC-3 pancreatic cancer cells in vitro. These studies show that the encapsulated inhibitor AKT/PDK1 in the nanoparticles is more accessible and thus more effective when compared with the drug alone, indicating their potential use in chemotherapeutic applications.",
keywords = "Controlled release, Mathematical modeling, Nanoparticles, Pancreatic cancer, Parametric analysis, PLGA",
author = "Armando Lucero-Acu{\~n}a and Guzman, {Roberto Z}",
year = "2015",
month = "10",
day = "15",
doi = "10.1016/j.ijpharm.2015.07.049",
language = "English (US)",
volume = "494",
pages = "249--257",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Nanoparticle encapsulation and controlled release of a hydrophobic kinase inhibitor

T2 - Three stage mathematical modeling and parametric analysis

AU - Lucero-Acuña, Armando

AU - Guzman, Roberto Z

PY - 2015/10/15

Y1 - 2015/10/15

N2 - A mathematical model of drug release that incorporates the simultaneous contributions of initial burst, nanoparticle degradation-relaxation and diffusion was developed and used to effectively describe the release of a kinase inhibitor and anticancer drug, PHT-427. The encapsulation of this drug into PLGA nanoparticles was performed by following the single emulsion-solvent evaporation technique and the release was determined in phosphate buffer pH 7.4 at 37 °C. The size of nanoparticles was obtained in a range of 162-254 nm. The experimental release profiles showed three well defined phases: an initial fast drug release, followed by a nanoparticle degradation-relaxation slower release and then a diffusion release phase. The effects of the controlled release most relevant parameters such as drug diffusivity, initial burst constant, nanoparticle degradation-relaxation constant, and the time to achieve a maximum rate of drug release were evaluated by a parametrical analysis. The theoretical release studies were corroborated experimentally by evaluating the cytotoxicity effectiveness of the inhibitor AKT/PDK1 loaded nanoparticles over BxPC-3 pancreatic cancer cells in vitro. These studies show that the encapsulated inhibitor AKT/PDK1 in the nanoparticles is more accessible and thus more effective when compared with the drug alone, indicating their potential use in chemotherapeutic applications.

AB - A mathematical model of drug release that incorporates the simultaneous contributions of initial burst, nanoparticle degradation-relaxation and diffusion was developed and used to effectively describe the release of a kinase inhibitor and anticancer drug, PHT-427. The encapsulation of this drug into PLGA nanoparticles was performed by following the single emulsion-solvent evaporation technique and the release was determined in phosphate buffer pH 7.4 at 37 °C. The size of nanoparticles was obtained in a range of 162-254 nm. The experimental release profiles showed three well defined phases: an initial fast drug release, followed by a nanoparticle degradation-relaxation slower release and then a diffusion release phase. The effects of the controlled release most relevant parameters such as drug diffusivity, initial burst constant, nanoparticle degradation-relaxation constant, and the time to achieve a maximum rate of drug release were evaluated by a parametrical analysis. The theoretical release studies were corroborated experimentally by evaluating the cytotoxicity effectiveness of the inhibitor AKT/PDK1 loaded nanoparticles over BxPC-3 pancreatic cancer cells in vitro. These studies show that the encapsulated inhibitor AKT/PDK1 in the nanoparticles is more accessible and thus more effective when compared with the drug alone, indicating their potential use in chemotherapeutic applications.

KW - Controlled release

KW - Mathematical modeling

KW - Nanoparticles

KW - Pancreatic cancer

KW - Parametric analysis

KW - PLGA

UR - http://www.scopus.com/inward/record.url?scp=84940062185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940062185&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2015.07.049

DO - 10.1016/j.ijpharm.2015.07.049

M3 - Article

VL - 494

SP - 249

EP - 257

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1

M1 - 15053

ER -